July 21st, 2018


Volume 63
Number 3
   
 Symposium
 Gestational Trophoblastic Disease Presentations from the XIXth World Congress on Gestational Trophoblastic Diseases
191
Ross S. Berkowitz, M.D., Neil S. Horowitz, M.D., Kevin M. Elias, M.D., and Donald P. Goldstein, M.D. Guest Editors


193
Elisabeth J. Diver, M.D., Neil S. Horowitz, M.D., Kevin M. Elias, M.D., Donald P. Goldstein, M.D., Ross S. Berkowitz, M.D., and Whitfield B. Growdon, M.D.
Women with postmolar gestational trophoblastic neoplasia who have failure of first-line chemotherapy and then are referred to a specialty center have a longer time to remission and require more lines of chemotherapy than women treated only after referral.


199
T. Rinda Soong, M.D., Ph.D., MPH, Michelle R. Davis, M.D., Kevin M. Elias, M.D., Neil S. Horowitz, M.D., Liping Yuan, M.D., Donald P. Goldstein, M.D., Ross S. Berkowitz, M.D., and Bradley J. Quade, M.D., Ph.D.
p57 immunohistochemistry reliably distinguishes partial from complete hydatidiform moles. Additional ancillary testing for identifying misclassification of moles is not significantly better than histology alone in predicting progression to gestational trophoblastic neoplasia.


209
Margaux J. Kanis, M.D., Richard A. Greendyk, M.D., Janelle Sobecki-Rausch, M.D., Megan E. Dayno, M.S., and John R. Lurain, M.D.
In treating high-risk gestational trophoblastic neoplasia with multiagent chemotherapy, granulocyte colony-stimulating factors administered as primary prophylaxis or secondarily decreases morbidity, treatment delays, and dose reductions, resulting in improved outcomes.


213
Annie Hills, R.N., Kam Singh, R.N., Jane Ireson, R.N., Sarah Gillett, R.N., Matthew Winter, M.D., Barry Hancock, M.D., and John Tidy, M.D.
One year’s experience of selecting partial moles for shortened follow-up, based on histopathology review, shows that this is of real benefit to these patients.


216
Lei Li, M.D., Xirun Wan, M.D., Fengzhi Feng, M.D., Tong Ren, M.D., Junjun Yang, M.D., Jun Zhao, M.D., Fang Jiang, M.D., and Yang Xiang, M.D.
Second-line regimens for low-risk postmolar gestational trophoblastic neoplasia resistant to single-agent treatment had similar remission rates. Courses of chemotherapy is an independent predictor of remission.


223
Maria Febi B. De Ramos, M.D., and Agnes L. Soriano-Estrella, M.D., M.H.P.Ed.
This is a retrospective cohort study to determine the significance of pulmonary metastases diagnosed only by chest computed tomography on the outcome of patients with low-risk gestational trophoblastic neoplasia.


228
Antonio Braga, M.D., Lana Lima, M.D., Raphael Câmara Medeiros Parente, M.D., Roger Keller Celeste, Ph.D., Jorge de Rezende Filho, M.D., Joffre Amim Junior, M.D., Izildinha Maestá, M.D., Sue Yazaki Sun, M.D., Elza Uberti, M.D., Lawrence Lin, M.D., José Mauro Madi, M.D., Maurício Viggiano, M.D., Kevin M. Elias, M.D., Neil S. Horowitz, M.D., and Ross S. Berkowitz, M.D.
Management of less severe bleeding complications of uterine arteriovenous malformations with depot medroxyprogesterone acetate and tranexamic acid is reasonable.


240
Vilmos Fülöp, M.D., Ph.D., D.Sc., Iván Szigetvári, M.D.,† János Szepesi, M.D., György Végh, M.D., János Demeter, M.D., and Ross S. Berkowitz, M.D.
Patients with high-risk metastatic gestational trophoblastic neoplasia should be treated primarily with EMA-CO combination chemotherapy, while surgery still plays a valuable role in the disease management.


249
Jan S. Erkamp, M.D., Marianne J. Ten Kate-Booij, M.D., Ph.D., Patricia Ewing-Graham, FRCPath, and Sam Schoenmakers, M.D., Ph.D.
The authors present a review focusing on the pathophysiology of symptoms of a complete hydatidiform mole and coexisting healthy twin.


254
Dan Wang, M.D., Fan Yu, M.D., Xinyan Liu, M.D., Juntao Liu, M.D., Xirun Wan, M.D., and Yang Xiang, M.D.
If severe maternal complications are controlled and fetal karyotype and development are normal, the pregnancy may be allowed to continue under close surveillance.


261
Antonio Braga, M.D., Priscila Oliveira de Souza, R.N., Ana Paula Vieira dos Santos Esteves, R.N., Ph.D., Lilian Padrón, M.D., Elza Uberti, M.D., Maurícío Viggiano, M.D., Sue Yazaki Sun, M.D., Izildinha Maestá, M.D., Kevin M. Elias, M.D., Neil Horowitz, M.D., Ross Berkowitz, M.D., and the Brazilian Network for Gestational Trophoblastic Disease Study Group
Due to the lack of robust scientific evidence regarding the management of gestational trophoblastic disease, consensus agreement among experts can be valuable.


271
Lawrence H. Lin, M.D., Koji Fushida, M.D., Ph.D., Maria Okumura, M.D., Ph.D., Regina Schultz, M.D., Ph.D., Rossana P. V. Francisco, M.D., Ph.D., and Marcelo Zugaib, M.D., Ph.D.
Epithelioid trophoblastic tumor is a rare trophoblastic neoplasm that is poorly responsive to chemotherapy; therefore, surgical resection is key in the management of this disease.


 Original Articles
276
Rebecca H. Stone, Pharm.D., Rebekah Anguiano, Pharm.D., Christina Bobowski, Pharm.D., Kristina Falk, Pharm.D., Pedro Alvarez, M.D., and Dimitrios Mastrogiannis, M.D.
There is significant latency from prescribing to administration of first dose when comparing compounded and commercial formulations of 17-hydroxyprogesterone caproate for prevention of preterm birth.


285
Taro Nonaka, M.D., Marie Tominaga, M.D., Makiko Takahashi, M.D., Chika Nonaka, M.D., Takayuki Enomoto, M.D., and Koichi Takakuwa, M.D.
Immunotherapy using paternal lymphocytes was suggested to be effective not only for patients with primary recurrent abortion but also for those with secondary recurrent abortion.


292
Brianna M. W. Lyttle, M.D., Angela K. Lawson, Ph.D., Susan Klock, Ph.D., Kristin Smith, B.S., Ralph Kazer, M.D., Jennifer Hirshfeld-Cytron, M.D., and Mary Ellen Pavone, M.D., MSCI
Sleep scores for infertile patients significantly increased during controlled ovarian hyperstimulation―often reaching values equivalent to national levels cited for chronic illnesses―but did not correlate with ovarian stimulation outcomes.


299
Norbert Pásztor, M.D., Zoltan Kozinszky, M.D., Ph.D., and Attila Keresztúri, M.D., Ph.D.
Maternal hypertensive disorders are the only distinguishable clinical features between growth restricted and non–intrauterine growth retardation stillbirths.


305
Gorkem Tuncay, M.D., and Cagatay Taskapan, M.D.
Higher vitamin D levels improve implantation rate and in vitro fertilization outcome without affecting the cycle characteristics or number of oocytes.


 Case Reports
311
Conisha Holloman, M.D., Stephen J. Carlan, M.D., and Veronica Schimp, D.O.
Retained placenta combined with uterine artery embolization may be a risk factor for de novo postpartum preeclampsia.


314
GuoHua Li, M.D., JingYu Shao, Ph.D., ShiHua Bao, Ph.D., and ShengMing Ruan, M.D.
Adequate and appropriate hormonal therapy is crucial to the pregnancy of a patient with Swyer syndrome.


317
Zeynep Soyman, M.D., Besim H. Bacanakgil, M.D., Serdar Kaya, M.D., and Mushviga Hasanova, M.D.
Endometriosis must be considered during the evaluation of an ovarian mass with ascites.


319
Sayaka Matsueda, M.D., Nobuhiro Hidaka, M.D., Ph.D., Yukiko Kondo, M.D., and Kiyoko Kato, M.D., Ph.D.
Live birth is achievable even in twin cesarean scar pregnancy with the aid of aggressive tocolysis to prevent massive bleeding and preterm birth.


 

The opinions and statements in this journal are those of the authors and are not attributable to the sponsor, publisher, editors or editorial board of JRM. Product dosages, indications and methods of use referred to in the papers and discussions reflect the authors' clinical experience or are derived from other professional sources.